Patterns of comorbidities in atrial fibrillation patients with high thromboembolic risks: a latent class analysis of two prospective registries from the Asia-Pacific and Europe
Long-term real-world outcomes of edoxaban in atrial fibrillation patients with and without prior ischaemic stroke: A 4-year follow-up analysis from ETNA-AF Europe
Interrupted or uninterrupted direct oral anticoagulants for atrial aibrillation ablation which is the best strategy insights from a network meta-analysis